Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells

Cytokine

Volumn 78, Issue , 2016, Pages 22-26

  Kim, Nayoun ^a,b   Jeon, Young Woo ^a,b,c   Nam, Young Sun ^a,b   Lim, Jung Yeon ^a,b   Im, Keon Il ^a,b   Lee, Eun Sol ^a,b   Cho, Seok Goo ^a,b,c  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Department of Laboratory of Immune Regulation   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Chronic graft versus host disease; Immunotherapy; Interleukin 2; Regulatory T cell

Indexed keywords

ALDESLEUKIN; BUSULFAN; FLUDARABINE PHOSPHATE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; TACROLIMUS; CYTOKINE; INTERLEUKIN 2; RECOMBINANT PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CATARACT; CATARACT EXTRACTION; CELL EXPANSION; CELLULITIS; CHRONIC GRAFT VERSUS HOST DISEASE; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOTOTHERAPY; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REGULATORY T LYMPHOCYTE; SCLERODERMA; TH17 CELL; WHOLE BODY RADIATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOTHERAPY; SUBCUTANEOUS DRUG ADMINISTRATION;

CELL PROLIFERATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; INFUSIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84947976049     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.11.020     Document Type: Article

References (14)

1. Ratanatharathorn V., Ayash L., Lazarus H.M., Fu J., Uberti J.P. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 2001, 28:121-129.
2. Chen X., Vodanovic-Jankovic S., Johnson B., Keller M., Komorowski R., Drobyski W.R. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007, 110:3804-3813.
3. Zorn E., Kim H.T., Lee S.J., Floyd B.H., Litsa D., Arumugarajah S., et al. Reduced frequency of FOXP3+ CD4+ CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005, 106:2903-2911.
4. Koreth J., Matsuoka K., Kim H.T., McDonough S.M., Bindra B., Alyea E.P., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 2011, 365:2055-2066.
5. Matsuoka K., Koreth J., Kim H.T., Bascug G., McDonough S., Kawano Y., et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci. Transl. Med. 2013, 5:179ra43.
6. Kennedy-Nasser A.A., Ku S., Castillo-Caro P., Hazrat Y., Wu M.F., Liu H., et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin. Cancer Res. 2014, 20:2215-2225.
7. Satake A., Schmidt A.M., Archambault A., Leichner T.M., Wu G.F., Kambayashi T. Differential targeting of IL-2 and T cell receptor signaling pathways selectively expands regulatory T cells while inhibiting conventional T cells. J. Autoimmun. 2013, 44:13-20.
8. Zeiser R., Nguyen V.H., Beilhack A., Buess M., Schulz S., Baker J., et al. Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.
9. Satake A., Schmidt A.M., Nomura S., Kambayashi T. Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in allogeneic bone marrow transplantation. PLoS ONE 2014, 9:e92888.
10. Perol L., Martin G.H., Maury S., Cohen J.L., Piaggio E. Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host disease. Immunol. Lett. 2014, 162:173-184.
11. Pilon C.B., Petillon S., Naserian S., Martin G.H., Badoual C., Lang P., et al. Administration of low doses of IL-2 combined to rapamycin promotes allogeneic skin graft survival in mice. Am. J. Transplant. 2014, 14:2874-2882.
12. Shin H.J., Baker J., Leveson-Gower D.B., Smith A.T., Sega E.I., Negrin R.S. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+ CD25+ Foxp3+ regulatory T cells. Blood 2011, 118:2342-2350.
13. Lee S.Y., Cho M.L., Oh H.J., Ryu J.G., Park M.J., Jhun J.Y., et al. Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2/STAT5 signalling pathways. Immunology 2012, 137:305-316.
14. Klatzmann D., Abbas A.K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 2015, 15:283-294.